Does TALIGLUCERASE ALFA Cause Infusion site extravasation? 5 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Infusion site extravasation have been filed in association with TALIGLUCERASE ALFA (ELELYSO). This represents 1.1% of all adverse event reports for TALIGLUCERASE ALFA.
5
Reports of Infusion site extravasation with TALIGLUCERASE ALFA
1.1%
of all TALIGLUCERASE ALFA reports
1
Deaths
2
Hospitalizations
How Dangerous Is Infusion site extravasation From TALIGLUCERASE ALFA?
Of the 5 reports, 1 (20.0%) resulted in death, 2 (40.0%) required hospitalization.
Is Infusion site extravasation Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TALIGLUCERASE ALFA. However, 5 reports have been filed with the FAERS database.
What Other Side Effects Does TALIGLUCERASE ALFA Cause?
Fatigue (59)
Arthralgia (43)
Off label use (43)
Pyrexia (40)
Malaise (39)
Pain (38)
Inappropriate schedule of product administration (37)
Pain in extremity (37)
Headache (36)
Nausea (33)
What Other Drugs Cause Infusion site extravasation?
HUMAN IMMUNOGLOBULIN G (822)
INFLIXIMAB (435)
INFLIXIMAB-DYYB (328)
TREPROSTINIL (256)
VEDOLIZUMAB (199)
HUMAN IMMUNOGLOBULIN G\HYALURONIDASE RECOMBINANT HUMAN (185)
REMDESIVIR (144)
FERRIC CARBOXYMALTOSE (118)
RITUXIMAB (82)
NATALIZUMAB (70)
Which TALIGLUCERASE ALFA Alternatives Have Lower Infusion site extravasation Risk?
TALIGLUCERASE ALFA vs TALIMOGENE LAHERPAREPVEC
TALIGLUCERASE ALFA vs TALQUETAMAB
TALIGLUCERASE ALFA vs TALQUETAMAB-TGVS
TALIGLUCERASE ALFA vs TAMIFLU
TALIGLUCERASE ALFA vs TAMOXIFEN